help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Essayan, D. M.
Right arrow Articles by Lichtenstein, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Essayan, D. M.
Right arrow Articles by Lichtenstein, L. M.

Am. J. Respir. Cell Mol. Biol., Vol 13, No. 6, 12 1995, 692-702.

Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells

DM Essayan, SK Huang, A Kagey-Sobotka and LM Lichtenstein
Division of Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland 21224, USA.

Cyclic nucleotide phosphodiesterase (PDE) enzymes may participate in regulation of the inflammatory response through their effects on second messengers. In the present study, we have investigated the role of nonselective and isozyme selective PDE inhibitors in altering the antigen-driven cytokine gene expression of peripheral blood mononuclear cells (PBMCs) from atopic individuals. Ragweed and tetanus toxoid were used as model antigens. The nonselective PDE inhibitor, 3-isobutyl-1- methylxanthine (IBMX), and the selective PDE4 inhibitor, rolipram, markedly suppressed interleukin-5 (IL-5) and interferon gamma (IFN gamma) gene expression in both antigen-driven systems. Gene expression for IL-4 was unaffected by these agents in the ragweed-driven system. Message for IL-4 could not be detected in the tetanus toxoid-driven system, despite the use of a quantitative, competitive reverse transcription-polymerase chain reaction (RT-PCR) assay sensitive to less than 10 fg of target template. The PDE3 inhibitor, siguazodan, was ineffective in downregulating gene expression for the proinflammatory cytokines assayed; when used in combination with the PDE4 inhibitor, the PDE3 inhibitor provided no increase in efficacy over that seen with the PDE4 inhibitor alone. Gene expression for the A and B isoforms of the PDE4 in PBMCs was unaffected by antigen stimulation or treatment with the PDE4 inhibitor; however, differences in expression of these two isoforms were apparent when a variety of immune cell lines were studied. These data support the hypothesis that the primary anti- inflammatory target for PDE inhibition in PBMCs is the PDE4. Furthermore, the expression of various isoforms of this enzyme may differ between immune cell types. Finally, PDE4 isoform expression in PBMCs is independent of treatment with an isozyme selective inhibitor.


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
P. E. Losco, E. W. Evans, S. A. Barat, P. E. Blackshear, L. Reyderman, J. S. Fine, L. A. Bober, J. C. Anthes, E. J. Mirro, and F. M. Cuss
The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys
Toxicol Pathol, April 1, 2004; 32(3): 295 - 308.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Jimenez, C. Punzon, J. Navarro, M. A. Munoz-Fernandez, and M. Fresno
Phosphodiesterase 4 Inhibitors Prevent Cytokine Secretion by T Lymphocytes by Inhibiting Nuclear Factor-kappa B and Nuclear Factor of Activated T Cells Activation
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 753 - 759.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. L. Baroja, L. B. Cieslinski, T. J. Torphy, R. L. Wange, and J. Madrenas
Specific CD3{varepsilon} Association of a Phosphodiesterase 4B Isoform Determines Its Selective Tyrosine Phosphorylation After CD3 Ligation
J. Immunol., February 15, 1999; 162(4): 2016 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. S. Barnette, S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy
SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions
J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 420 - 426.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
G. G. Bashian, C. M. Braun, S.-K. Huang, A. Kagey-Sobotka, L. M. Lichtenstein, and D. M. Essayan
Differential Regulation of Human, Antigen-specific Th1 and Th2 Responses by the B-7 Homologues, CD80 and CD86
Am. J. Respir. Cell Mol. Biol., August 1, 1997; 17(2): 235 - 242.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Essayan, A. Kagey-Sobotka, L. M. Lichtenstein, and S.-K. Huang
Differential Regulation of Human Antigen-Specific Th1 and Th2 Lymphocyte Responses by Isozyme Selective Cyclic Nucleotide Phosphodiesterase Inhibitors
J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 505 - 512.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. J. TORPHY
Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1995 American Thoracic Society. 		  ATS Best of the Web